MESENCHYMAL STEM CELLS HAVING ENHANCED OSTEOGENIC DIFFERENTIATION CAPACITY, AND USE THEREOF

• Main Authors: KONG, Taeho, AN, Borim, WON, Jihye, KIM, Junsung, RIM, Jong Seop, LEE, Soonchul
• Format: Patent
• Language: English; French; German
• Published: 13.03.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES; VINEGAR; WINE

According to one aspect, provided are mesenchymal stem cells (MSCs) having enhanced osteogenic differentiation capacity, having excellent osteogenic differentiation capacity, adipogenic differentiation capacity, chondrogenic differentiation capacity, and neurogenic differentiation capacity, and particularly, significantly superior osteogenic differentiation capacity to MSCs derived from other sources. In addition, the MSCs having enhanced osteogenic differentiation capacity exhibit low immunological rejection and have effects of preventing or treating a bone disease and estrogen deficiency syndrome. Furthermore, proliferative ability and karyotype stability of the MSCs having enhanced osteogenic differentiation capacity are maintained even after continuous subculturing, and thus the MSCs having enhanced osteogenic differentiation capacity are safe for commercialization and capable of being mass-produced.